These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 24982455)

  • 1. Reply to B. Freidlin et al.
    Vergote I; Coens C; Casado A; Jimeno A
    J Clin Oncol; 2014 Aug; 32(22):2388. PubMed ID: 24982455
    [No Abstract]   [Full Text] [Related]  

  • 2. Transparency in interim monitoring.
    Freidlin B; Korn EL
    J Clin Oncol; 2014 Aug; 32(22):2387-8. PubMed ID: 24982465
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose-dense effect: other contributors - author's reply.
    Katsumata N
    Lancet Oncol; 2013 Nov; 14(12):e489-90. PubMed ID: 24176564
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversy in treatment of advanced ovarian cancer.
    Scambia G; Salutari V; Amadio G
    Lancet Oncol; 2013 Sep; 14(10):920-1. PubMed ID: 23993374
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-dense effect: other contributors.
    Kesikli SA; Yuce D; Kilickap S
    Lancet Oncol; 2013 Nov; 14(12):e489. PubMed ID: 24176565
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
    Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
    J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to M.L. Friedlander et al.
    Colombo N
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930277
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to M.L. Friedlander et al.
    Spriggs DR
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930276
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?
    Vergote I; Leunen K; Amant F
    Gynecol Oncol; 2012 Jan; 124(1):1-2. PubMed ID: 22153125
    [No Abstract]   [Full Text] [Related]  

  • 11. Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy.
    Lim MC; Park SY
    Gynecol Oncol; 2012 May; 125(2):510. PubMed ID: 22266549
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view.
    Tomao F; Tomao S; Panici PB
    J Clin Oncol; 2013 Jan; 31(1):166-7. PubMed ID: 23169499
    [No Abstract]   [Full Text] [Related]  

  • 13. Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
    Holmberg LA; Goff B; Veljovich D
    Gynecol Oncol; 2011 May; 121(2):426. PubMed ID: 21324515
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on "Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery".
    Barton DP; Naik R; Pomel C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1104-5. PubMed ID: 22914211
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?
    Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA
    J Clin Oncol; 2013 Jun; 31(18):2362. PubMed ID: 23669225
    [No Abstract]   [Full Text] [Related]  

  • 16. VEGF inhibitors and advanced ovarian cancer.
    Jayson G
    Lancet Oncol; 2011 Nov; 12(12):1082-3. PubMed ID: 21992854
    [No Abstract]   [Full Text] [Related]  

  • 17. Nintedanib and ovarian cancer: standardise surgery in trials?
    Kehoe S
    Lancet Oncol; 2016 Jan; 17(1):9-11. PubMed ID: 26590674
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug development for chronic cancers: time to think differently?
    Spriggs DR
    J Clin Oncol; 2012 Nov; 30(31):3779-80. PubMed ID: 22987092
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
    Juretzka M; Hensley ML; Tew W; Konner J; Aghajanian C; Leitao M; Iasonos A; Soslow R; Park K; Sabbatini P
    Eur J Gynaecol Oncol; 2008; 29(6):568-72. PubMed ID: 19115680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in ovarian cancer: unanswered questions.
    Muggia F
    Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.